This is a working overview of Melanotan II, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.
18q deletion syndrome Acrodermatitis enteropathica Acrogeria (Gottron syndrome) Acrokeratosis verruciformis (acrokeratosis verruciformis of Hopf) Adams–Oliver syndrome Adducted thumbs syndrome Albright's hereditary osteodystrophy Angelman syndrome Apert syndrome (acrocephalosyndactyly) Arthrogryposis–renal dysfunction–cholestasis syndrome Ataxia telangiectasia (Louis–Bar syndrome) Atrichia with papular lesions (papular atrichia) Atrophodermia vermiculata (acne vermoulante, acne vermoulanti, atrophoderma reticulata symmetrica faciei, atrophoderma reticulatum, atrophoderma vermiculata, atrophoderma vermiculatum, atrophodermia reticulata symmetrica faciei, atrophodermia ulerythematosa, atrophodermie vermiculée des joues avec kératoses folliculaires, folliculitis ulerythema reticulata, folliculitis ulerythematous reticulata, folliculitis ulerythemosa, honeycomb atrophy, ulerythema acneforme, ulerythema acneiforme) Autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome Bart syndrome Bazex–Dupré–Christol syndrome (Bazex syndrome, follicular atrophoderma and basal cell carcinomas) Beare–Stevenson cutis gyrata syndrome Bloom syndrome (Bloom–Torre–Machacek syndrome) Blue rubber bleb nevus syndrome Brittle hair–intellectual impairment–decreased fertility–short stature syndrome Cantú syndrome Cardio-facio-cutaneous syndrome (cardiofaciocutaneous syndrome) Cartilage–hair hypoplasia (McKusick type metaphyseal chondrodysplasia) Cerebral dysgenesis–neuropathy–ichthyosis–keratoderma syndrome Childhood tumor syndrome Chondrodysplasia punctata Cicatricial junctional epidermolysis bullosa Craniosynostosis–anal anomalies–porokeratosis syndrome Cockayne syndrome Colobomas of the eye–heart defects–ichthyosiform dermatosis–mental retardation–ear defects syndrome (CHIME syndrome, Zunich neuroectodermal syndrome, Zunich–Kaye syndrome) Congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome (CHILD syndrome) Conradi–Hünermann syndrome (Conradi–Hünermann–Happle syndrome, Happle syndrome, X-linked dominant chondrodysplasia punctata) Costello syndrome Cronkhite–Canada syndrome Crouzon syndrome Cutis verticis gyrata Darier's disease (Darier–White disease, dyskeratosis follicularis, keratosis follicularis) DeSanctis–Cacchione syndrome Disseminated superficial actinic porokeratosis Disseminated superficial porokeratosis Dolichol kinase deficiency Dominant dystrophic epidermolysis bullosa Dyskeratosis congenita (Zinsser–Cole–Engman syndrome) Dystrophic epidermolysis bullosa Ectodermal dysplasia Ectodermal dysplasia with corkscrew hairs Ectrodactyly–ectodermal dysplasia–cleft syndrome (EEC syndrome, split hand–split foot–ectodermal dysplasia–cleft syndrome) Epidermolysis bullosa herpetiformis (Dowling–Meara epidermolysis bullosa simplex) Epidermolysis bullosa simplex Epidermolysis bullosa simplex of Ogna Epidermolysis bullosa simplex with mottled pigmentation Epidermolysis bullosa simplex with muscular dystrophy Epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma, bullous ichthyosiform erythroderma) Erythrokeratodermia with ataxia (Giroux–Barbeau syndrome) Familial benign chronic pemphigus (familial benign pemphigus, Hailey–Hailey disease) Fanconi syndrome (familial pancytopenia, familial panmyelophthisis) Fibrodysplasia ossificans progressiva Focal dermal hypoplasia (Goltz syndrome) Follicular atrophoderma Franceschetti–Klein syndrome (mandibulofacial dysostosis) Gardner's syndrome (familial colorectal polyposis) Gastrocutaneous syndrome Generalized atrophic benign epidermolysis bullosa Generalized epidermolysis bullosa simplex (Koebner variant of generalized epidermolysis bullosa simplex) Generalized trichoepithelioma Giant axonal neuropathy with curly hair Gingival fibromatosis with hypertrichosis Haber syndrome Hallerman–Streiff syndrome Harlequin-type ichthyosis (harlequin baby, harlequin fetus, harlequin ichthyosis, ichthyosis congenita, ichthyosis congenita gravior) Hay–Wells syndrome (AEC syndrome, ankyloblepharon filiforme adnatum–ectodermal dysplasia–cleft palate syndrome, ankyloblepharon–ectodermal defects–cleft lip and palate syndrome, ankyloblepharon–ectodermal dysplasia–clefting syndrome) Hereditary sclerosing poikiloderma Heterochromia iridum Holocarboxylase synthetase deficiency Hypohidrotic ectodermal dysplasia (anhidrotic ectodermal dysplasia, Christ–Siemens–Touraine syndrome) Hypotrichosis–acro-osteolysis–onychogryphosis–palmoplantar keratoderma–periodontitis syndrome Hypotrichosis–lymphedema–telangiectasia syndrome Ichthyosis–brittle hair–impaired intelligence–decreased fertility–short stature syndrome (IBIDS syndrome, sulfur-deficient brittle hair syndrome, Tay's syndrome, trichothiodystrophy, trichothiodystrophy with ichthyosis) Ichthyosis bullosa of Siemens (ichthyosis exfoliativa) Ichthyosis follicularis (ichthyosis follicularis with alopecia and photophobia syndrome) Ichthyosis linearis circumflexa Ichthyosis prematurity syndrome Ichthyosis vulgaris (autosomal dominant ichthyosis, ichthyosis simplex) Ichthyosis with confetti Neonatal ichthyosis–sclerosing cholangitis syndrome (ichthyosis–sclerosing cholangitis syndrome, NISCH syndrome) Incontinentia pigmenti achromians (hypomelanosis of Ito) Immune dysfunction–polyendocrinopathy–enteropathy–X-linked syndrome Jaffe–Campanacci syndrome Johanson–Blizzard syndrome Johnson–McMillin syndrome Joubert syndrome Junctional epidermolysis bullosa Junctional epidermolysis bullosa gravis (epidermolysis bullosa letalis, Herlitz disease, Herlitz epidermolysis bullosa, Herlitz syndrome, lethal junctional epidermolysis bullosa) Junctional epidermolysis bullosa with pyloric atresia Kabuki syndrome (Kabuki makeup syndrome, Niikawa–Kuroki syndrome) Keratolytic winter erythema (erythrokeratolysis hiemalis, Oudtshoorn disease, Oudtshoorn skin) Keratosis follicularis spinulosa decalvans (Siemens-1 syndrome) Keratosis linearis with ichthyosis congenita and sclerosing keratoderma syndrome Keratosis pilaris atrophicans faciei (folliculitis rubra, keratosis pilaris rubra atrophicans faciei, lichen pilare, lichen pilaire ou xerodermie pilaire symmetrique de la face, ulerythema ophryogenes, xerodermi pilaire symmetrique de la face) Keratosis pilaris Kindler syndrome (acrokeratotic poikiloderma, bullous acrokeratotic poikiloderma of Kindler and Weary, congenital poikiloderma with blisters and keratoses, congenital poikiloderma with bullae and progressive cutaneous atrophy, hereditary acrokeratotic poikiloderma, hyperkeratosis–hyperpigmentation syndrome, Weary–Kindler syndrome) Klinefelter syndrome Klippel–Feil syndrome Lamellar ichthyosis (collodion baby) Legius syndrome (neurofibromatosis type 1-like syndrome) Lelis syndrome Lenz–Majewski syndrome Leschke syndrome Lethal acantholytic epidermolysis bullosa Lhermitte–Duclos disease Linear and whorled nevoid hypermelanosis (linear nevoid hyperpigmentation, progressive cribriform and zosteriform hyperpigmentation, reticulate and zosteriform hyperpigmentation, reticulate hyperpigmentation of Iijima and Naito and Uyeno, zebra-like hyperpigmentation in whorls and streaks, zebra-line hyperpigmentation) Linear Darier disease (acantholytic dyskeratotic epidermal nevus) Linear porokeratosis Localized epidermolysis bullosa simplex (Weber–Cockayne syndrome, Weber–Cockayne variant of generalized epidermolysis bullosa simplex) Mandibuloacral dysplasia Marinesco–Sjögren syndrome McCune–Albright syndrome McCusick syndrome Metageria Microphthalmia–dermal aplasia–sclerocornea syndrome Mitis junctional epidermolysis bullosa (nonlethal junctional epidermolysis bullosa) Mitochondrial myopathy–encephalopathy–lactic acidosis–stroke syndrome Multiple lentigines syndrome (cardiocutaneous syndrome, Gorlin syndrome II, lentiginosis profusa syndrome, LEOPARD syndrome, progressive cardiomyopathic lentiginosis) Multiple pterygium syndrome Multiple sulfatase deficiency (Austin disease, mucosulfatidosis) Naegeli–Franceschetti–Jadassohn syndrome (chromatophore nevus of Naegeli) Netherton syndrome Neurofibromatosis type 1 (von Recklinghausen's disease) Neurofibromatosis type 3 (neurofibromatosis mixed type) Neurofibromatosis type 4 (neurofibromatosis variant type) Neutral lipid storage disease (Dorfman–Chanarin syndrome) Nonbullous congenital ichthyosiform erythroderma (congenital ichthyosiform erythroderma) Noonan syndrome Oculocerebrocutaneous syndrome (Delleman–Oorthuys syndrome) Oculodentodigital dysplasia Odonto-tricho-ungual-digital-palmar syndrome Oliver–McFarlane syndrome Orofaciodigital syndrome Pachydermoperiostosis (idiopathic hypertrophic osteoathorpathy, Touraine–Solente–Gole syndrome) Peeling skin syndrome (acral peeling skin syndrome, continual peeling skin syndrome, familial continual skin peeling, idiopathic deciduous skin, keratolysis exfoliativa congenita) Pfeiffer syndrome Photosensitivity–ichthyosis–brittle sulfur-deficient hair–impaired intelligence–decreased fertility–short stature syndrome Pityriasis rotunda (pityriasis circinata, tinea circinata) Plate-like osteoma cutis Plaque-type porokeratosis (classic porokeratosis, porokeratosis of Mibelli) Polyneuropathy–organomegaly–endocrinopathy–monoclonal gammopathy–skin changes syndrome (Crow–Fukase syndrome) Polyostotic fibrous dysplasia (Albright's disease) Popliteal pterygium syndrome Porokeratosis Porokeratosis palmaris et plantaris disseminata Prader–Willi syndrome Progeria (Hutchinson–Gilford progeria syndrome, Hutchinson–Gilford syndrome, progeria syndrome) Progressive osseous heteroplasia Progressive symmetric erythrokeratodermia (erythrokeratodermia progressiva symmetrica) Proteus syndrome Proteus-like syndrome Punctate porokeratosis Rapp–Hodgkin syndrome (Rapp–Hodgkin ectodermal dysplasia syndrome) Recessive dystrophic epidermolysis bullosa (Hallopeau–Siemens variant of epidermolysis bullosa, Hallopeau–Siemens disease) Refsum's disease (heredopathia atactica polyneuritiformis, phytanic acid storage disease) Relapsing linear acantholytic dermatosis Restrictive dermopathy Rhizomelic chondrodysplasia punctata (autosomal recessive chondrodysplasia punctata type 1, chondrodystrophia calcificans punctata, peroxisomal biogenesis disorder complementation group 11) Rombo syndrome Rothmund–Thomson syndrome (poikiloderma congenitale) Rud syndrome Say syndrome Scalp–ear–nipple syndrome (Finlay–Marks syndrome) Schindler disease (Kanzaki disease, alpha-N-acetylgalactosaminidase deficiency) Schinzel–Giedion syndrome Scleroatrophic syndrome of Huriez (Huriez syndrome, palmoplantar keratoderma with scleroatrophy, palmoplantar keratoderma with sclerodactyly, scleroatrophic and keratotic dermatosis of the limbs, sclerotylosis) Segmental neurofibromatosis Senter syndrome (Desmons' syndrome) Shabbir syndrome (laryngo–onycho–cutaneous syndrome) Silver–Russell syndrome Sjögren–Larsson syndrome Skin fragility syndrome (plakophilin 1 deficiency) Smith–Lemli–Opitz syndrome Sturge–Weber syndrome Supernumerary nipples–uropathies–Becker's nevus syndrome Terminal osseous dysplasia with pigmentary defects Tooth and nail syndrome (hypodontia with nail dysgenesis, Witkop syndrome) Townes–Brocks syndrome Transient bullous dermolysis of the newborn Treacher Collins syndrome (Treacher Collins–Franceschetti syndrome) Tricho–dento–osseous syndrome Tricho–rhino–phalangeal syndrome Tuberous sclerosis (Bourneville disease, epiloia) Turner syndrome Ulnar–mammary syndrome Van Der Woude syndrome Von Hippel–Lindau syndrome Watson syndrome Werner syndrome (adult progeria) Westerhof syndrome Whistling syndrome (craniocarpotarsal syndrome, distal arthrogryposis type 2, Freeman–Sheldon syndrome, Windmill–Vane–Hand syndrome) Wilson–Turner syndrome Wolf–Hirschhorn syndrome (4p- syndrome) X-linked ichthyosis (steroid sulfatase deficiency, X-linked recessive ichthyosis) X-linked recessive chondrodysplasia punctata Xeroderma pigmentosum (Cockayne syndrome complex) XXYY genotype Zimmermann–Laband syndrome
In seemingly rare cases, medications such as SSRIs, isotretinoin (Accutane) and finasteride (Propecia) are reported to induce long-lasting iatrogenic disorders characterized by sexual dysfunction symptoms, including erectile dysfunction in males; these disorders are known as post-SSRI sexual dysfunction (PSSD), post-retinoid sexual dysfunction/post-Accutane syndrome (PRSD/PAS), and post-finasteride syndrome (PFS). These conditions remain poorly understood and lack effective treatments, although they have been suggested to share a common etiology.
== Overview and assessment of Kermani’s literary work by Torsten Hoffmann == Torsten Hoffmann, a literary scholar, a professor at the University of Stuttgart, and a recognized and long-standing expert on Kermani's extensive literary work, classifies Kermani’s narrative work as follows: Most of Kermani’s literary texts draw on an auto-fictionalapproach (in his most extensive novel, „Dein Name“ [Your Name], the protagonist is also named “Navid Kermani”). Furthermore, they are characterizing by a particular interest in fundamental human experiences such as birth, love, and death, along with a programmatic combination of (sometimes drastic) everydayness with an affinity for art (including literature, music, film, and the visual arts) and religiosity. The boundaries between his works of fiction and works more commonly regarded as nonfiction (such as „Ungläubiges Staunen“ (Wonder Beyond Belief) or „Jeder soll von da, wo er ist, einen Schritt näher kommen“ (Everyone, Wherever You Are, Come One Step Closer) and travelogues are fluid. For while Kermani’s nonfiction books often employ literary narrative techniques, conversely, many of his works of fiction contain essayistic passages.
Sources: en.wikipedia.org
== Pharmacology == Nordazepam is a partial agonist at the GABAA receptor, which makes it less potent than other benzodiazepines, particularly in its amnesic and muscle-relaxing effects. Its elimination half-life is between 36 and 200 hours, with wide variation among individuals; factors such as age and sex are known to impact it. The variation of reported half-lives are attributed to differences in nordazepam metabolism and that of its metabolites as nordazepam is hydroxylated to active metabolites such as oxazepam, before finally being glucuronidated and excreted in the urine. This can be attributed to extremely variable hepatic and renal metabolic functions among individuals depending upon a number of factors (including age, ethnicity, disease, and current or previous use/abuse of other drugs/medicines).
Complicated intra-abdominal infections; Acute pyelonephritis; Complicated urinary tract infections. Hospital-acquired bacterial pneumonia and Ventilator-associated bacterial pneumonia (HABP/VABP) In addition, ceftolozane/tazobactam has demonstrated stability for administration by continuous infusion, including delivery via elastomeric pumps. This pharmacotechnical property supports its use in outpatient parenteral antimicrobial therapy (OPAT) programs, particularly for time-dependent β-lactam optimization and carbapenem-sparing strategies. In real-world OPAT cohorts, ceftolozane/tazobactam accounted for approximately 7.5% of antibiotics administered by continuous infusion.
== Iron malabsorption == Instant coffee decreases intestinal iron absorption more than drip coffee. One study estimated that, when a cup of instant coffee was ingested with a meal composed of semi-purified ingredients, intestinal absorption was reduced from 5.88% to 0.97%, compared to an absorption of 1.64% with drip coffee. It was also estimated that, when the strength of the instant coffee was doubled, intestinal iron absorption fell to 0.53%. However, there is no decrease in iron absorption when instant coffee is consumed 1 hour before a meal, but the same degree of inhibition as with simultaneous ingestion occurs when instant coffee is taken 1 hour after a meal.
Reformist Mikhail Gorbachev, General Secretary of the Communist Party of the Soviet Union, also wished to reduce defence expenditures, including the enormous open-ended commitment of military aid to FAPLA, and was more open to a political settlement accordingly.
Another potential strategy that can facilitate rapid assembly and enhance stability of DNA bricks is the use of the kinetically interlocking multiple-unit (KIMU) strategy. This strategy was used to determine if multiple unit-DNA (MUD) strands could improve structural stability and accelerate the annealing process for medium to long length DNA strands compared to the traditional short-strand DNA brick assemblies. The KIMU theory suggests that increasing the number of noncovalent units can improve the stability of DNA assembly, create DNA bricks with lengths of ~50 nucleotides, and increase collision between DNA bricks. The MUD assemblies increased the local concentration of nucleotide units and enabled well-assembled DNA structures to recover more readily through kinetic interlocking after dissolution. This interlocking, facilitated by the interaction among multiple units, enhanced the stability of the previous assembly composed entirely of short DNA strands, offering an alternative strategy to fabricate longer but stable DNA structures.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.